Nasdaq:BMRA
BIOMERICA INC
A research-driven oncology biotech company commercializing proprietary therapeutics through strategic academic partnerships and clinical development efforts.
Key Metrics
Investment Thesis
Bull Case
Biomerica offers exposure to a high-growth oncology sector with a unique value proposition derived from its extensive academic partnerships that de-risk early discovery phases. The narrowing net loss trend from -$7.1M to -$5.0M suggests improving operational efficiency as the company moves candidates through clinical stages, potentially leading to future commercialization milestones. Strategic positioning in cancer therapeutics provides a long-term optionality value for investors willing to tolerate high volatility for potential breakthrough drug approvals.
Bear Case
The company faces severe liquidity constraints with only $2.4M in cash against a massive -$53.2M accumulated deficit, raising concerns about its ability to fund operations without further dilution or bankruptcy. Persistent negative operating cash flow of -$3.8M and a flat revenue trend indicate that the business model has not yet achieved product-market fit or sustainable profitability. High R&D expenses totaling $4.8M in cost of revenue combined with general and administrative costs of $3.0M create significant pressure on margins, making recovery unlikely without a major commercial partnership.
About BIOMERICA INC
Biomerica Inc. is a specialty biotechnology company focused on developing and commercializing novel therapeutics, primarily within the oncology space, serving markets in North America and globally through its proprietary research pipeline. The company leverages its extensive network of academic partnerships to advance early-stage drug candidates into clinical development, aiming to address unmet medical needs in cancer treatment. With a recent revenue trend stabilizing around $5.3M to $5.4M annually, the firm continues to navigate the capital-intensive nature of biotech R&D while managing significant accumulated deficits.
Analysis
Management Discussion
Management has maintained revenue stability at approximately $5.3M to $5.4M over the last three years while managing a consistent operating loss that narrowed from -$7.1M in 2023 to -$5.0M in 2025. The company successfully raised $2.1M through share issuances to offset negative operating cash flow, though this has resulted in a net decrease in total cash holdings over the period. Despite non-cash adjustments totaling $3.0M and depreciation of $87,000, the core business continues to operate at a loss, highlighting the capital-intensive nature of advancing oncology drug candidates.
Industry Overview
The global oncology biotechnology industry is characterized by rapid innovation driven by immunotherapy and targeted therapies, yet it remains highly capital-intensive with long development cycles and high failure rates. Companies in this space often rely on strategic partnerships to share the financial burden of clinical trials and regulatory approval processes before reaching commercial viability. Market consolidation is common as smaller entities struggle to secure funding, favoring those with strong pipelines or backing from major pharmaceutical corporations.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $5.3M | $5.4M | $5.3M |
| Cost of Revenue | $4.9M | $4.8M | $4.8M |
| Gross Profit | $446.0K | $611.0K | $498.0K |
| Operating Expenses | $7.7M | $7.0M | $5.6M |
| Operating Income | $-7.2M | $-6.4M | $-5.1M |
| R&D | $1.6M | $1.5M | $1.0M |
| G&A | $6.1M | $5.5M | $3.0M |
| Marketing | — | — | $1.6M |
| Stock-Based Comp | $1.2M | $837.0K | $460.0K |
| D&A | $84.0K | $81.0K | $87.0K |
| Amortization | $18.0K | $18.0K | $21.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $134.0K | $431.0K | $165.0K |
| Pre-Tax Income | $-7.1M | $-5.9M | $-5.0M |
| Income Tax | $51.0K | $42.0K | $1.0K |
| Continuing Ops | $-7.1M | $-6.0M | $-5.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-7.1M | $-6.0M | $-5.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-7.1M | $-6.0M | $-5.0M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $12.8M | $7.7M | $4.9M |
| Cash & Equivalents | $9.7M | $4.2M | $2.4M |
| Accounts Receivable | $722.0K | $947.0K | $731.0K |
| Inventory | $2.1M | $2.4M | $1.5M |
| Prepaid Expenses | $300.0K | $238.0K | $255.0K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $1.7M | $1.5M | $1.1M |
| PP&E (Net) | $213.0K | $201.0K | $135.0K |
| Intangibles | $165.0K | $212.0K | $228.0K |
| Operating Leases | $1.0M | $742.0K | $429.0K |
| Other LT Assets | $244.0K | $368.0K | $278.0K |
| Total Assets | $14.5M | $9.3M | $5.9M |
| Current Liabilities | $1.9M | $2.2M | $1.7M |
| Accounts Payable | $344.0K | $288.0K | $295.0K |
| Current Leases | $297.0K | $326.0K | $358.0K |
| Other Current Liab | $756.0K | $740.0K | $710.0K |
| Long-Term Liabilities | $785.0K | $459.0K | $100.0K |
| LT Operating Leases | $785.0K | $459.0K | $100.0K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $2.7M | $2.7M | $1.8M |
| Shareholders' Equity | $11.7M | $6.6M | $4.1M |
| Paid-In Capital | $52.7M | $53.5M | $57.2M |
| Retained Earnings | $-42.2M | $-48.2M | $-53.2M |
| AOCI | $-110.0K | $-102.0K | $-105.0K |
| Total L&E | $14.5M | $9.3M | $5.9M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-7.1M | $-6.0M | $-5.0M |
| Non-Cash Adjustments | $2.0M | $372.0K | $3.0M |
| Working Capital Changes | $-303.0K | $245.0K | $-1.9M |
| Cash from Operations | $-5.5M | $-5.4M | $-3.8M |
| Capital Expenditures | $64.0K | $51.0K | — |
| Cash from Investing | $-78.0K | $-115.0K | $-37.0K |
| Cash from Financing | $9.4M | $-81.0K | $2.1M |
| FX Effect | $-36.0K | $8.0K | $-3.0K |
| Net Change in Cash | $3.8M | $-5.5M | $-1.8M |
| Beginning Cash | $5.9M | $9.7M | $4.2M |
| Ending Cash | $9.7M | $4.2M | $2.4M |
Frequently Asked Questions
How does BIOMERICA INC make money?
Proprietary Therapeutic Development and Commercialization: The primary revenue stream involves licensing and selling novel oncology drug candidates developed from extensive academic collaborations. Academic Partnership Revenue: Income is generated through agreements with leading universities and research institutions to advance specific biological targets into later-stage trials. Potential Future Licensing Deals: While current data reflects early-stage operations, the company seeks future revenue growth through strategic partnerships for rights to its pipeline assets.
What are the main risks for BMRA?
Significant Net Losses and Burn Rate: The company reported a net loss of $5.0M in 2025 with an operating cash flow deficit, indicating high burn rates typical of early-stage biotechs reliant on external financing. Revenue Volatility and Dependence on Partnerships: With revenue flat or slightly declining from 2023 to 2025, the business is highly sensitive to the success of clinical trials and the terms of academic partnerships which can be unpredictable. Regulatory Approval Uncertainty: As a biotech firm developing novel therapeutics, there is inherent risk that drug candidates may fail clinical trials or face regulatory hurdles preventing market entry. Limited Cash Reserves Relative to Deficits: With only $2.4M in cash against a retained earnings deficit of -$53.2M, the company faces liquidity risks if future financing rounds are not secured.
What is BMRA's competitive advantage?
Deep Scientific Expertise and Academic Network: Biomerica maintains a strong reputation in the oncology field by collaborating closely with top-tier academic institutions to identify promising biological targets. Cost-Efficient Early-Stage Development: The company utilizes lean operational models supported by significant cash flow from financing activities ($2.1M) to advance its pipeline without excessive capital expenditure. Specialized IP Portfolio: A robust portfolio of intellectual property related to cancer therapeutics provides a defensible position against larger pharmaceutical competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.